Logo Image

Circulating Tumor DNA and Minimal Residual Disease Testing Across Solid Tumors

EP. 1: Foundations of ctDNA and MRD Testing

ByJohn Strickler, MD,Petros Grivas MD, PhD,Luis E. Raez, MD,Eleonora Teplinsky, MD,Benjamin Weinberg, MD

Dr. John Strickler introduces the program on circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing across solid tumors, joined by Dr. Eleonora Teplinsky (breast and gynecologic oncology, Valley Health System), Dr. Ben Weinberg (gastrointestinal oncology, Georgetown University), Dr. Petros Grivas (genitourinary oncology, Fred Hutchinson Cancer Center), and Dr. Luis Raez (thoracic oncology, Memorial Healthcare System).

EP. 2: Clinical Workflow Integration for ctDNA Testing and Patient Communication

ByJohn Strickler, MD,Petros Grivas MD, PhD,Luis E. Raez, MD,Eleonora Teplinsky, MD,Benjamin Weinberg, MD

Dr. Teplinsky addresses where ctDNA and MRD testing fit within the patient care continuum, noting that value isn't uniform across disease stages or tumor types. The strongest signal currently exists in the post-treatment surveillance setting, where tumor-informed assays can identify patients at higher recurrence risk before disease becomes visible on imaging.